{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:27:38Z","timestamp":1793273258972,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["RP-PG-0707-10124"],"award-info":[{"award-number":["RP-PG-0707-10124"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12883-016-0606-3","type":"journal-article","created":{"date-parts":[[2016,6,16]],"date-time":"2016-06-16T01:41:43Z","timestamp":1466041303000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["A review of clinical trial designs used to detect a disease-modifying effect of drug therapy in Alzheimer\u2019s disease and Parkinson\u2019s disease"],"prefix":"10.1186","volume":"16","author":[{"given":"David J. M.","family":"McGhee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig W.","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Zajicek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl E.","family":"Counsell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,16]]},"reference":[{"key":"606_CR1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088854","volume":"9","author":"DJ McGhee","year":"2014","unstructured":"McGhee DJ, Ritchie CW, Thompson PA, Wright DE, Zajicek JP, Counsell CE. A systematic review of biomarkers for disease progression in Alzheimer's disease. PLoS One. 2014;9, e88854.","journal-title":"PLoS One."},{"key":"606_CR2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2377-13-35","volume":"13","author":"DJ McGhee","year":"2013","unstructured":"McGhee DJ, Royle PL, Thompson PA, Wright DE, Zajicek JP, Counsell CE. A systematic review of biomarkers for disease progression in Parkinson's disease. BMC Neurol. 2013;13:35.","journal-title":"BMC Neurol."},{"key":"606_CR3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/mds.20057","volume":"19","author":"CE Clarke","year":"2004","unstructured":"Clarke CE. A \"cure\" for Parkinson's disease: can neuroprotection be proven with current trial designs? Mov Disord. 2004;19:491\u20138.","journal-title":"Mov Disord."},{"key":"606_CR4","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1212\/WNL.0b013e318199049e","volume":"72","author":"O Rascol","year":"2009","unstructured":"Rascol O. \"Disease-modification\" trials in Parkinson disease: target populations, endpoints and study design. Neurology. 2009;72:S51\u20138.","journal-title":"Neurology."},{"key":"606_CR5","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/mds.21918","volume":"23","author":"CE Clarke","year":"2008","unstructured":"Clarke CE. Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed? Mov Disord. 2008;23:784\u20139.","journal-title":"Mov Disord."},{"issue":"5","key":"606_CR6","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/mds.22432","volume":"24","author":"RG Hart","year":"2009","unstructured":"Hart RG, Pearce LA, Ravina BM, Yaltho TC, Marler JR. Neuroprotection trials in Parkinson's disease: systematic review. Mov Disord. 2009;24(5):647\u201354.","journal-title":"Mov Disord"},{"key":"606_CR7","unstructured":"Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity-maximizing version (2008) revision; OVID format. Cochrane Handbook for Systematic Reviews of Interventions. Edited by Higgins J, Green S. 2011. The Cochrane Collaboration. http:\/\/handbook.cochrane.org\/ . Accessed 14 Oct 2015."},{"key":"606_CR8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1742-7622-5-13","volume":"5","author":"C Lefebvre","year":"2008","unstructured":"Lefebvre C, Eisinga A, McDonald S, Paul N. Enhancing access to reports of randomized trials published world-wide--the contribution of EMBASE records to the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library. Emerg Themes Epidemiol. 2008;5:13.","journal-title":"Emerg Themes Epidemiol."},{"key":"606_CR9","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1212\/01.wnl.0000201252.57661.e1","volume":"66","author":"The NINDS NET-PD Investigators","year":"2006","unstructured":"The NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology. 2006;66:664\u201371.","journal-title":"Neurology."},{"key":"606_CR10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1212\/01.wnl.0000250355.28474.8e","volume":"68","author":"The NINDS NET-PD Investigators","year":"2007","unstructured":"The NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology. 2007;68:20\u20138.","journal-title":"Neurology."},{"key":"606_CR11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/jamaneurol.2013.5528","volume":"71","author":"MA Schwarzschild","year":"2014","unstructured":"Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, Hare JM, et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014;71:141\u201350.","journal-title":"JAMA Neurol."},{"key":"606_CR12","doi-asserted-by":"crossref","unstructured":"NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol. 2015;14:795\u2013803.","DOI":"10.1016\/S1474-4422(15)00144-1"},{"key":"606_CR13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR. \"Mini-mental state\". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189\u201398.","journal-title":"J Psychiatr Res"},{"key":"606_CR14","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/00002093-199700112-00003","volume":"11","author":"RC Mohs","year":"1997","unstructured":"Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11:S13\u201321.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"606_CR15","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412\u20134.","journal-title":"Neurology."},{"key":"606_CR16","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","volume":"123","author":"I Aviles-Olmos","year":"2013","unstructured":"Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T, et al. Exenatide and the treatment of patients with Parkinson's disease. J Clin Invest. 2013;123:2730\u20136.","journal-title":"J Clin Invest."},{"key":"606_CR17","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/mds.20213","volume":"19","author":"CG Goetz","year":"2004","unstructured":"Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004;19:1020\u20138.","journal-title":"Mov Disord."},{"key":"606_CR18","first-page":"153","volume-title":"Recent Developments in Parkinson's Disease","author":"S Fahn","year":"1987","unstructured":"Fahn S, Eton RL, UPDRS Development Committee. The Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne D, editors. Recent Developments in Parkinson's Disease. Florham Park, New Jersey: Macmillan Healthcare Information; 1987. p. 153\u201363."},{"key":"606_CR19","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1001\/jama.2009.1866","volume":"302","author":"RC Green","year":"2009","unstructured":"Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA. 2009;302:2557\u201364.","journal-title":"JAMA."},{"key":"606_CR20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/ana.410400116","volume":"40","author":"The Parkinson Study Group","year":"1996","unstructured":"The Parkinson Study Group. Effect of lazabemide on the progression of disability in early Parkinson's disease. Ann Neurol. 1996;40:99\u2013107.","journal-title":"Ann Neurol"},{"key":"606_CR21","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMoa0809335","volume":"361","author":"CW Olanow","year":"2009","unstructured":"Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Eng J Med. 2009;361:1268\u201378.","journal-title":"N Eng J Med."},{"key":"606_CR22","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJM199704243361704","volume":"336","author":"M Sano","year":"1997","unstructured":"Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. New Engl J Med. 1997;336:1216\u201322.","journal-title":"New Engl J Med"},{"key":"606_CR23","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/archgenpsychiatry.2011.72","volume":"68","author":"PN Tariot","year":"2011","unstructured":"Tariot PN, Schneider LS, Cummings J, Thomas RG, Raman R, Jakimovich LJ, et al. Alzheimer's Disease Cooperative Study Group. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry. 2011;68:853\u201361.","journal-title":"Arch Gen Psychiatry"},{"key":"606_CR24","unstructured":"Sunphenon EGCg (Epigallocatechin-Gallate) in the early stage of Alzheimer's disease (SUN-AK). ClinicalTrials.gov. 2015. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00951834 . Accessed 22 Sep 2015."},{"key":"606_CR25","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1001\/jama.289.21.2819","volume":"289","author":"PS Aisen","year":"2003","unstructured":"Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003;289:2819\u201326.","journal-title":"JAMA."},{"key":"606_CR26","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1056\/NEJM199301213280305","volume":"328","author":"The Parkinson Study Group","year":"1993","unstructured":"The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Eng J Med. 1993;328:176\u201383.","journal-title":"N Eng J Med"},{"key":"606_CR27","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/syn.890180203","volume":"18","author":"JS Fowler","year":"1994","unstructured":"Fowler JS, Volkow ND, Logan J, Wang GJ, MacGregor RR, Schyler D, et al. Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal. Synapse. 1994;18:86\u201393.","journal-title":"Synapse."},{"key":"606_CR28","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1126\/science.2502843","volume":"245","author":"JW Tetrud","year":"1989","unstructured":"Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science. 1989;245:519\u201322.","journal-title":"Science."},{"key":"606_CR29","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2006.07.001","volume":"2","author":"JL Cummings","year":"2006","unstructured":"Cummings JL. Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials. Alzheimers Dement. 2006;2:263\u201371.","journal-title":"Alzheimers Dement."},{"key":"606_CR30","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/ana.20789","volume":"59","author":"AH Schapira","year":"2006","unstructured":"Schapira AH, Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol. 2006;59:559\u201362.","journal-title":"Ann Neurol."},{"key":"606_CR31","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1212\/WNL.0b013e3181d7d94b","volume":"74","author":"CW Olanow","year":"2010","unstructured":"Olanow CW, Rascol O. The delayed-start study in Parkinson disease: can't satisfy everyone. Neurology. 2010;74:1149\u201350.","journal-title":"Neurology."},{"key":"606_CR32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/1740774510392391","volume":"8","author":"C Xiong","year":"2011","unstructured":"Xiong C, van Belle G, Miller JP, Morris JC. Designing clinical trials to test disease-modifying agents: application to the treatment trials of Alzheimer's disease. Clin Trials. 2011;8:15\u201326.","journal-title":"Clin Trials"},{"key":"606_CR33","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMsm0904209","volume":"361","author":"RB D'Agostino Sr","year":"2009","unstructured":"D'Agostino Sr RB. The delayed-start study design. N Engl J Med. 2009;361:1304\u20136.","journal-title":"N Engl J Med."},{"key":"606_CR34","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1517\/14656566.2011.548807","volume":"12","author":"JR Evans","year":"2011","unstructured":"Evans JR, Barker RA. Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease. Expert Opin Pharmacother. 2011;12:1249\u201358.","journal-title":"Expert Opin Pharmacother."},{"key":"606_CR35","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ana.24188","volume":"76","author":"E Karran","year":"2014","unstructured":"Karran E, Hardy J. A critique of the drug discovery and phase 3 clincial programs targeting the amyloid hypothesis for Alzheimer disease. Ann Neurol. 2014;76:185\u2013205.","journal-title":"Ann Neurol."},{"key":"606_CR36","doi-asserted-by":"crossref","unstructured":"Chakraborty H, Gu H. A mixed model approach for intent-to-treat analysis in longitudinal clinical trials with missing values. RTI Press. 2009. http:\/\/www.rti.org\/rtipress (Publication No. MR-0009-0903). Accessed 14 Oct 2015.","DOI":"10.3768\/rtipress.2009.mr.0009.0903"},{"key":"606_CR37","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/0021-9681(67)90041-0","volume":"20","author":"D Schwartz","year":"1967","unstructured":"Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis. 1967;20:637\u201348.","journal-title":"J Chronic Dis."},{"key":"606_CR38","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/bmj.319.7211.670","volume":"319","author":"S Hollis","year":"1999","unstructured":"Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ. 1999;319:670\u20134.","journal-title":"BMJ."},{"key":"606_CR39","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/archneur.59.10.1541","volume":"59","author":"CW Shults","year":"2002","unstructured":"Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002;59:1541\u201350.","journal-title":"Arch Neurol."},{"key":"606_CR40","doi-asserted-by":"crossref","first-page":"d40","DOI":"10.1136\/bmj.d40","volume":"342","author":"IR White","year":"2011","unstructured":"White IR, Horton NJ, Carpenter J, Pocock SJ. Strategy for intention to treat analysis in randomised trials with missing outcome data. BMJ. 2011;342:d40.","journal-title":"BMJ."},{"key":"606_CR41","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/jnnp-2014-307703","volume":"86","author":"D McGhee","year":"2015","unstructured":"McGhee D, Parker A, Fielding S, Zajicek J, Counsell C. Using \u2018dead or dependent\u2019 as an outcome measure in clincial trials in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2015;86:180\u20135.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"606_CR42","unstructured":"European Study of 3APS in Mild to Moderate Alzheimer's Disease Patients. 2007. ClinicalTrials.gov. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00217763 . Accessed 9 Oct 2015."}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-016-0606-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T16:13:04Z","timestamp":1568045584000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-016-0606-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,16]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["606"],"URL":"https:\/\/doi.org\/10.1186\/s12883-016-0606-3","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,16]]},"article-number":"92"}}